Healthcare Industry News: IRRAflow catheter
News Release - April 6, 2021
IRRAS Announces Collaboration with Aarhus University Hospital, Scandinavian Leader in Neurosurgery, to Advance Use of IRRAflowThe collaboration with Aarhus University's neurosurgical team will evaluate IRRAflow during the treatment of Intraventricular Hemorrhage (IVH) and assessment of brain compliance
STOCKHOLM, April 6, 2021 -- (Healthcare Sales & Marketing Network) -- IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, today announced a strategic collaboration with Aarhus University Hospital (AAUH) in Aarhus, Denmark, one of Scandinavia's leading medical institutions.
Dr. Anders Korshøj, Associate Professor of Neurosurgery at Aarhus University Hospital, will lead the collaboration that will unite specialists from the hospital's neurocritical care team and data analytics experts from The Aarhus University Center for Digitalization, Big Data and Data Analytics. The collaboration will focus initially upon the use of the company's IRRAflow system to treat patients suffering from intraventricular hemorrhage (IVH). The facility's use of IRRAflow in the treatment of IVH will be prospectively compared to the use of traditional drainage treatments in the pending ACTIVE clinical study. Beyond this study, other clinical and product development projects are also being planned.
Aarhus University Hospital is an 854-bed academic teaching hospital that, in 2020, was named Denmark's best hospital for the 13th consecutive year by healthcare newspaper, Dagens Medicin. The institution was also recently ranked as the 11th best hospital in the world by the American publication, Newsweek. The hospital's Departments of Neurosurgery and Neurointensive Care are leaders throughout all of Scandinavia as the departments are responsible for both general and highly specialized procedures for patients across all of Denmark.
IRRAflow is the world's first "irrigating intracranial drain" and its unique mechanism of action addresses the complications associated with the current methods of managing intracranial fluid by using a dual-lumen catheter that combines automated irrigation, controlled drainage, and continuous monitoring of intracranial pressure (ICP), all within one system.
"It is my belief that the system's combination of automated irrigation and controlled drainage should contribute to better long-term outcomes for these critically ill patients," said Dr. Korshøj. "Furthermore, we believe that the system's ability to measure pressure immediately after fluid movement is uniquely capable of measuring real-time intracranial compliance, and I am excited to partner with IRRAS to explore these hypotheses in greater detail."
Traditional treatment options for IVH patients generally utilize an external ventricular drainage (EVD) system, which is a passive approach that relies solely on gravity to facilitate drainage. Although an EVD is currently the most common treatment option for intracranial bleeding or elevated ICP, the technology is associated with several well-known complications such as catheter blockage, infections, and incomplete drainage. All of these complications can negatively impact patient outcome, which can subsequently increase the length of time needed in the hospital and the overall cost of care.
"This collaboration with Aarhus University Hospital represents an important component of our launch strategy for IRRAflow," said Will Martin, President and Chief Commercial Officer of IRRAS. "There is a compelling need in markets around the globe for transformative technologies, such as IRRAflow, to treat patients with intracranial bleeding, and we believe that our collaboration with Aarhus University Hospital to collect clinical data will advance the treatment of IVH and also accelerate the product's awareness to a wider group of neurocritical care specialists."
IRRAS is a global medical care company focused on delivering innovative medical solutions to improve the lives of critically ill patients. IRRAS designs, develops, and commercializes neurocritical care products that transform patient outcomes and decrease the overall cost of care by addressing complications associated with current treatment methodologies. IRRAS markets and sells its comprehensive, innovative IRRAflow and Hummingbird ICP Monitoring product lines to hospitals worldwide through its direct sales organization in the United States and select European countries as well as an international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit www.irras.com.
IRRAS AB (publ) is listed on Nasdaq Stockholm (ticker: IRRAS).
Source: IRRAS AB
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.